Entera Bio Ltd. announced the appointment of Geno J. Germano as Chairman of the Board, succeeding Gerald Lieberman. The company plans to move two oral PTH peptide programs into clinical testing in 2026. Mr. Germano expressed excitement about the potential of EB613 to revolutionize osteoporosis treatment by offering an oral alternative to injections. His extensive pharmaceutical leadership experience will be valuable as Entera enters a pivotal phase of development. Entera is focused on developing oral peptide therapies for various medical needs, including osteoporosis, hypoparathyroidism, obesity, and rare malabsorption conditions. For more information, visit www.enterabio.com.

Read more at GlobeNewswire: Entera Bio Appoints Former Pfizer Executive Geno J. Germano